Providing an extra layer of barrier protection for HCP’s to prevent airborne pathogen exposure during aerosolized procedures.

GermShield™ Highlights:

  • Sets up in seconds
  • Packaged flat to save space
  • Single use provides safety and time savings
  • Optically clear for excellent visibility
  • 7/8″ port(s) enables localized negative pressure

Call Now to learn more about GermShield™ +1 888 978 7087

GermShield shown with GermVac negative pressure unit

Protect Your Staff

Reduce Risk

Increase Safety

Call Now to learn more about GermShield™ +1 888 978 7087

This product has not been FDA cleared or approved.

This product has been authorized by FDA under an EUA for use by healthcare providers (HCP) when caring for or performing medical procedures on patients who are known or suspected to have COVID-19, in healthcare settings, to prevent HCP exposure to pathogenic biological airborne particulates by providing an extra layer of barrier protection in addition to personal protective equipment.

This product is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices, including alternative products used as medical devices, during the COVID-19 outbreak, under section 564(b)(1) of the Act, 21 U.S.C.§360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.

©2020 Aerobiotix, Inc. GermShield, Aerobiotix, and the A logo are trademarks of Aerobiotix, Inc.

MG 100-A


President and CEO

The founder and CEO is David Kirschman, M.D., a former physician with extensive experience as CEO, Director, Chief Scientific Officer and operator in the orthopedic and biologic medical device space. Dr. Kirschman holds 55 issued US Patents for a wide range of medical devices. He received his BS in Biological Science cum laude from Colorado State University and M.D. from University of Colorado School of Medicine.


Director Scientific Affairs

Dr. Carroll has extensive experience in ultraviolet and photonic science. Prior to joining Aerobiotix, he led the research and development group at Sunstar Engineering. He has a Ph.D. in chemistry from Columbia University and did his postdoctoral fellowship under Nobel laureate Prof. Ben Feringa at the University of Groningen, Netherlands, and Lawrence Berkeley National Laboratory.


Chief Commercial Officer

Tony leads our global sales organization and commercialization strategy. Prior joining Aerobiotix, he was Senior Manager of Strategy at Stryker. He has led sales and marketing teams in multiple organizations including SurgiCount Medical, part of Patient Safety Technologies, INC (PSTX) as it expanded from 8 hospitals in 2008 to user base of 330 hospitals at time of acquisition in 2013.


VP of Clinical and Medical Affairs

Dr. Adams leads our global clinical research and education initiatives as well as developing key opinion leaders to support our clinical mission. Prior to joining Aerobiotix, she held leading research and medical affairs roles at Biogen, Axogen, and MedPace. Dr. Adams holds Ph.D. in Pharmacology from University of Cincinnati.


Vice President of Engineering

Anthony is a topflight medical device product development engineer and leader, experienced in the development and implementation of orthopedic, environmental, and electromechanical systems.


Vice President of Sales

Nathan brings a high level of commitment to servicing and building client relations. He was one of the first employees to start for Aerobiotix. Nathan has previously held leadership roles in the medical device industry. He received his BS from Antioch McGregor University Midwest.


Chief Financial Officer

Mr. Schmitz is a highly experienced financial practitioner with financial leadership roles in diverse industries including manufacturing and technology as well as a background in public accounting. He received his BS in accounting, cum laude, from the Miami University of Ohio. Mr. Schmitz is a certified public accountant and certified management accountant.